RT Journal Article
SR Electronic
T1 Direct influence of BMPR2 mutations on cytokine patterns and biomarker effectiveness in pulmonary arterial hypertension
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.05.21253970
DO 10.1101/2021.05.05.21253970
A1 Max Schwiening
A1 Emilia M Swietlik
A1 Divya Pandya
A1 Keith Burling
A1 Peter Barker
A1 Carmen Treacy
A1 Susana Abreu
A1 S. John Wort
A1 Joanna Pepke-Zaba
A1 Stefan Graf
A1 Stefan J Marciniak
A1 Nicholas Morrell
A1 Elaine Soon
A1 members of the UK National Cohort Study of Idiopathic and Heritable PAH
YR 2021
UL http://medrxiv.org/content/early/2021/05/07/2021.05.05.21253970.abstract
AB Background Pulmonary arterial hypertension (PAH) covers a range of life-limiting illnesses characterized by increased pulmonary arterial pressures leading to right heart failure and death, if untreated. 15-25% of patients have genetic mutations, the most common affecting bone morphogenetic protein receptor type 2 (BMPR2). The aim was to define an inflammatory cytokine profile in BMPR2-mutation positive patients and analyze their influence on survival.Methods Levels of cytokines were measured in plasma samples from BMPR2-mutation positive patients (BMPR2mut, n=54), patients without any driving mutations (n=54), and healthy controls (n=56) recruited from the United Kingdom cohort.Findings BMPR2-mutation positive patients and patients without mutations had high levels of interleukin-6, interleukin-8, tumor necrosis factor-α, and vascular endothelial growth factor-A compared to controls. Only BMPR2-mutation carrying patients had higher G-CSF levels compared to controls. VEGF-A levels were substantially higher in patients without mutations compared to the BMPR2mut group. Interleukin-6 was a significant discriminator for mortality in the BMPR2mut cohort (cumulative survival with interleukin-6≥1.6pg/ml at 3 years was 65% compared to 96% with interleukin-6<1.6pg/ml, P=0·0013). N-Terminal pro-B-Type natriuretic peptide levels did not discriminate for survival in our BMPR2mut cohort (cumulative survival for patients with an NT-proBNP>130ng/ml at 3 years was 76% compared to 84% for patients with an NT-proBNP≤130ng/ml, P=0·37). NT-proBNP outperformed interleukin-6 in PAH without mutations.Interpretation BMPR2-mutation positivity has a direct impact not only on inflammatory profiles but also on effectiveness of prognostic biomarkers. In our BMPR2-mutation positive cohort IL-6 was the strongest prognostic biomarker and NT-proBNP failed to discriminate for survival.What is the key question?Do pulmonary arterial hypertension patients who are BMPR2-mutation positive have a different cytokine signature than PAH patients without mutations?What is the bottom line?BMPR2-mutation positive and PAH patients without mutations display different patterns of cytokine elevation and these cytokines differ in the way they influence transplant-free survival.Why read on?In our cohort of BMPR2-mutation positive patients, IL-6 is the best prognostic biomarker while NT-proBNP failed to discriminate for survival – this implies that prognostic biomarkers and by inference treatments could be genotype-specific.TAKE HOME MESSAGE BMPR2-mutation positive patients have different inflammatory and growth factor profiles compared to PAH patients without mutations. Interleukin-6 is an effective biomarker for transplant-free survival in our cohort of BMPR2-mutation positive patients while NT-proBNP is ineffective. Conversely, NT-proBNP appears to be a more effective biomarker for pulmonary arterial patients without any mutations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the Medical Research Council (UK), the Josephine Lansdell award (British Medical Association) and the Association of Physicians of Great Britain and Ireland (ES and MS). CBAL (KB and PB) is partially funded by the NIHR Cambridge Biomedical Centre. SA and SJM are funded from the British Lung Foundation and the Medical Research Council (UK). The UK National Cohort of Idiopathic and Heritable PAH (CMT, DP, EMS, SG and NWM) is supported by the National Institute for Health Research (NIHR), the British Heart Foundation (BHF) (SP/12/12/29836), the BHF Cambridge Centre of Cardiovascular Research Excellence, the UK Medical Research Council (MR/K020919/1), the Dinosaur Trust, BHF Programme grants to NWM (RG/13/4/30107), and the UK NIHR Cambridge Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study complies with the Declaration of Helsinki and was given ethical approval by the National Research Ethics Service (NRES) committee for the East of England (REC REF: 13/EE/0325 and 13/EE/0203). The NRES oversees research in the National Health Service (UK). All participants gave informed written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article will be shared on reasonable request to the corresponding author. The requester must have appropriate ethical permissions for this to happen.